Galectin Therapeutics (GALT) Cash from Financing Activities (2010 - 2026)

Galectin Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $257000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $257000.0; the TTM figure through Mar 2026 stood at $26.7 million (up 25.93% YoY), while the FY2025 annual figure was $26.5 million, down 15.22% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $257000.0, down from $12.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $12.9 million in Q2 2025, with the low at $257000.0 in Q1 2026.
• The 5-year median for Cash from Financing Activities is $10.0 million (2022), against an average of $8.3 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 91.49% in 2024, then jumped 1337.96% in 2025.
• Galectin Therapeutics' Cash from Financing Activities stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then slumped by 91.49% to $851000.0 in 2024, then surged by 1337.96% to $12.2 million in 2025, then plunged by 97.9% to $257000.0 in 2026.
• Business Quant data shows GALT's Cash from Financing Activities at $257000.0 in Q1 2026, $12.2 million in Q4 2025, and $1.3 million in Q3 2025.